A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer
This is a Phase 2 study of oral dacomitinib given every 12 hours over days 1-4 of each two-week cycle to patients with Non-small cell lung cancer. The study includes two groups of patients, those whose tumor has a documented T790M mutation, and those without this mutation. All patients will receive repeated cycles of dacomitinib until disease progression, occurrence of unacceptable toxicity, or other withdrawal criteria are met.
Checked against the public recordLast updated Jul 18, 2017 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- Pfizer
- Interventions being studied
- Drug: Dacomitinib; Drug: Dacomitinib
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Evidence of histologically confirmed, advanced NSCLC (stage IIIB/IV). * Evidence of T790M mutation to enroll in Cohort A. * Evidence of measurable disease by radiographic technique. * Adequate organ function. Exclusion Criteria: * Patients with T790M mutation who stopped any prior EGFR-directed therapy without evidence of disease progression. * Symptomatic brain metastases. * Uncontrolled or significant cardiovascular disease. * Pregnant or breastfeeding.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Tower Hematology Oncology Medical GroupBeverly Hills, California
- Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer InstituteLos Angeles, California
- Georgetown University Hospital-Lombardi Comprehensive Cancer CenterWashington D.C., District of Columbia
- Georgetown University Medical Center Department of Pharmacy, ResearchWashington D.C., District of Columbia
- Memorial Sloan-Kettering Cancer Center-Rockefeller Outpatient PavilionNew York, New York
- Investigational Drug Service, Hillman Cancer CenterPittsburgh, Pennsylvania
- University of Pittsburgh Medical CenterPittsburgh, Pennsylvania
- UPMC Hillman Cancer CenterPittsburgh, Pennsylvania
- UT Southwestern Medical Center-Simmons Cancer Center PharmacyDallas, Texas
- UT Southwestern Medical CenterDallas, Texas
- UT Southwestern University Hospital - William P. Clements, Jr.Dallas, Texas
- UT Southwestern University Hospital - Zale LipshyDallas, Texas
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 18, 2017. Always confirm current availability with the study team.